Skip to content
value.today

Journey Medical Corporation

DERM
$187 Mmarket cap on Oct 5, 2026+102.8% since Jan 2024
Compare
World rank
#16,509
Revenue
$62 M
For year ending December-2025
Net income
$-11 M
-18.5% margin
SEC filing
Employees
58
As of March 18, 2026
SEC filing

Journey Medical Corporation in brief

Journey Medical Corporation is a listed company in the Biotechnology industry, based in Scottsdale, Arizona, USA. Its market value was $187 M on 5 October 2026, which makes it the 16,509th largest listed company in the world and the 3,193rd largest in the USA on this site. In the year to December 2025 it had sales of $62 M and a net loss of $11 M. It employs about 58 people and Claude Maraoui is its chief executive. Its largest product and service lines by sales in 2025 were Qbrexza (40%), Emrosi (24%) and Accutane (21%). Its shares trade under the symbol DERM (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Journey Medical Corporation

We are a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration approved prescription pharmaceutical products for the treatment of dermatological conditions. Our current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. We acquire rights to products and product candidates by licensing or otherwise acquiring an ownership interest in, funding the research and development of, and eventually commercializing the products through our field sales organization. We are a controlled subsidiary of Fortress Biotech, Inc..

From the company's annual report filed with the US SEC: read the report

Journey Medical Corporation timeline

3 events, 2021–2023
  1. 2021
  2. 🔔
    · approximate
    Initial public offering on Nasdaq
  3. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  4. 2023
  5. 💰
    Record revenue of $79 million
    FY2023, the highest of the 6 years on record.

Events of Journey Medical Corporation from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$70 M$139 M$209 M$279 M2023202420252026

World rank over time

▲ up 12,454 places since 2022
2022-12-25: #29091#29,09120222023-07-30: #27331#27,33120232024-01-05: #21887#21,88720242026-03-08: #8583#8,58320262026-08-01: #15571#15,57120262026-10-05: #16637#16,6372026

Rank in USA: #5,261 (Dec 2022) · #4,970 (Jul 2023) · #3,752 (Jan 2024) · #1,590 (Mar 2026) · #3,133 (Aug 2026) · #3,213 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
2.7×
Price / book
5.9×
Free cash flow yield
-12.9%
Net margin (TTM)
-7.3%
Operating margin
-13.2%
Return on equity
-16.0%
Liabilities / assets
66.3%
Net debt
$1M
Revenue growth
+10.2%
R&D / revenue
0.8%
Revenue per employee
$1.1 M
Profit per employee
$-197 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2020: revenue $45M, net income $5M$45MFY20Fiscal year ending Dec 2021: revenue $63M, net income $-44M$63MFY21Fiscal year ending Dec 2022: revenue $74M, net income $-30M$74MFY22Fiscal year ending Dec 2023: revenue $79M, net income $-4M$79MFY23Fiscal year ending Dec 2024: revenue $56M, net income $-15M$56MFY24Fiscal year ending Dec 2025: revenue $62M, net income $-11M$62MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$62M+10.2%$-8M$-11M-18.5%
Dec 2024$56M-29.1%$-14M$-15M-26.1%
Dec 2023$79M+7.5%$-2M$-4M-4.9%
Dec 2022$74M+16.7%$-28M$-30M-40.2%
Dec 2021$63M+41.8%$-35M$-44M-69.7%
Dec 2020$45M—$8M$5M11.9%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-12M——$-0.47—
Dec 2024$-9M$15M$-24M$-0.72—
Dec 2023$5M$5M$0M$-0.21—
Dec 2022$-14M$20M$-34M$-1.69—
Dec 2021$-2M——$-4.32—
Dec 2020$5M——$0.49—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$70M
Net income, trailing 12 months
$-5M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $14M, net income $2M$14MDec ’24Three months to Mar 2025: revenue $13M, net income $-4M$13MMar ’25Three months to Jun 2025: revenue $15M, net income $-4M$15MJun ’25Three months to Sep 2025: revenue $18M, net income $-2M$18MSep ’25Three months to Dec 2025 (from the annual report): revenue $16M, net income $-1M$16MDec ’25Three months to Mar 2026: revenue $16M, net income $-2M$16MMar ’26Three months to Jun 2026: revenue $19M, net income $-0M$19MJun ’26Three months to Sep 2026: revenue $19M, net income $-1M$19MSep ’26

Latest quarter to Sep 2026: revenue $19M (+7.6% on a year earlier), net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Journey Medical Corporation with the US Securities and Exchange Commission.

Annual results

Revenue
$62 M
Operating income
$-8 M
Net income
$-11 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$95 M
Total liabilities
$63 M
Total equity
$32 M

As of December-2025

Top 74 institutional investors in Journey Medical Corporation#

As of Sep 30, 2026
74 institutions held 11.0 M shares (about 40.2% of the shares outstanding) on Sep 30, 2026. The ten largest hold 28.3%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Journey Medical Corporation
#InstitutionShares heldChange (shares)% heldValueFiled
1Wasatch Advisors LP2,449,253-409,677 (-14.33%)8.98%$17 MOct 13, 2026
2Tang Capital Management LLC1,610,0000 (0.00%)5.90%$11 MNov 16, 2026
3Punch & Associates Investment Management, Inc.858,082+322,082 (+60.09%)3.15%$6 MNov 16, 2026
4Vanguard Capital Management LLC675,1850 (0.00%)2.48%$5 MNov 13, 2026
5Pale Fire Capital SE521,841-6,743 (-1.28%)1.91%$4 MNov 13, 2026
6First Eagle Investment Management, LLC483,207New1.77%$3 MNov 10, 2026
7Summit Financial, LLC344,214-2,534 (-0.73%)1.26%$2 MNov 12, 2026
8Diametric Capital, LP284,448-11,215 (-3.79%)1.04%$2 MNov 16, 2026
9Ikarian Capital, LLC251,4360 (0.00%)0.92%$2 MNov 16, 2026
10Two Sigma Investments, LP240,817New0.88%$2 MNov 16, 2026
11Millennium Management LLC239,696+129,680 (+117.87%)0.88%$2 MNov 16, 2026
12Renaissance Technologies LLC228,900-800 (-0.35%)0.84%$2 MNov 12, 2026
13Geode Capital Management, LLC202,066-13,938 (-6.45%)0.74%$1 MNov 6, 2026
14Marshall Wace, LLP194,311+54,468 (+38.95%)0.71%$1 MNov 13, 2026
15American Financial Group Inc180,0000 (0.00%)0.66%$1 MNov 12, 2026
16UBS Group AG160,066+76,552 (+91.66%)0.59%$1 MNov 10, 2026
17Opaleye Management Inc.125,000-225,000 (-64.29%)0.46%$1 MNov 16, 2026
18Morgan Stanley122,073+80,049 (+190.48%)0.45%$1 MNov 13, 2026
19Trexquant Investment LP121,154-50,184 (-29.29%)0.44%$1 MNov 16, 2026
20Jane Street Group, LLC118,576-201,445 (-62.95%)0.43%$1 MNov 12, 2026
21Squarepoint Ops LLC103,899+58,494 (+128.83%)0.38%$1 MNov 9, 2026
22BlackRock, Inc.96,189-4,792 (-4.75%)0.35%$1 MNov 13, 2026
23Vanguard Fiduciary Trust Co94,7290 (0.00%)0.35%$1 MNov 13, 2026
24Goldman Sachs Group Inc84,894-5,400 (-5.98%)0.31%$1 MNov 16, 2026
25PVG Asset Management Corp79,5730 (0.00%)0.29%$1 MOct 19, 2026
Show all 74: investors 26 to 74
Institutional investors 26 to 74 in Journey Medical Corporation
#InstitutionShares heldChange (shares)% heldValueFiled
26State Street Corp70,578+4,600 (+6.97%)0.26%$0 MNov 12, 2026
27Boothbay Fund Management, LLC67,4420 (0.00%)0.25%$0 MNov 16, 2026
28XTX Topco Ltd67,163-33,760 (-33.45%)0.25%$0 MNov 16, 2026
29Geneos Wealth Management Inc.63,2800 (0.00%)0.23%$0 MNov 9, 2026
30J. Goldman & Co LP56,655-80,929 (-58.82%)0.21%$0 MNov 16, 2026
31Envestnet Asset Management Inc54,435-11,390 (-17.30%)0.20%$0 MNov 16, 2026
32Citadel Advisors LLC51,464-30,685 (-37.35%)0.19%$0 MNov 16, 2026
33Frec Markets, Inc.50,5000 (0.00%)0.19%$0 MNov 16, 2026
34HRT Financial LP45,292New0.17%$0 MNov 13, 2026
35Integrated Wealth Concepts LLC39,750+172 (+0.43%)0.15%$0 MNov 17, 2026
36ADAR1 Capital Management, LLC39,5170 (0.00%)0.14%$0 MNov 16, 2026
37Northern Trust Corp35,6560 (0.00%)0.13%$0 MNov 16, 2026
38Salem Investment Counselors Inc35,319+6,119 (+20.96%)0.13%$0 MOct 13, 2026
39Susquehanna International Group, LLP30,724+10,723 (+53.61%)0.11%$0 MNov 16, 2026
40Qube Research & Technologies Ltd29,735New0.11%$0 MNov 13, 2026
41Schonfeld Strategic Advisors LLC27,787New0.10%$0 MNov 16, 2026
42Walleye Capital LLC24,720-40,742 (-62.24%)0.09%$0 MNov 13, 2026
43Prelude Capital Management, LLC20,548-1,357 (-6.19%)0.08%$0 MNov 16, 2026
44Gladstone Institutional Advisory LLC20,0000 (0.00%)0.07%$0 MNov 13, 2026
45Focus Partners Wealth19,392New0.07%$0 MNov 12, 2026
46Bank Of America Corp /de/18,788-23,119 (-55.17%)0.07%$0 MNov 16, 2026
47Invesco Ltd.16,187-492 (-2.95%)0.06%$0 MNov 12, 2026
48Jefferies Financial Group Inc.15,500-1,097 (-6.61%)0.06%$0 MNov 5, 2026
49Jain Global LLC15,463New0.06%$0 MNov 16, 2026
50Axq Capital, LP14,973New0.05%$0 MNov 12, 2026
51Mariner, LLC14,771+1,423 (+10.66%)0.05%$0 MNov 12, 2026
52BNP Paribas Financial Markets14,629-32,782 (-69.14%)0.05%$0 MNov 12, 2026
53D. E. Shaw & Co., Inc.12,785New0.05%$0 MNov 16, 2026
54Brighton Jones LLC12,380-322 (-2.54%)0.05%$0 MNov 3, 2026
55Jump Financial, LLC11,872New0.04%$0 MNov 13, 2026
56Arrowstreet Capital, Limited Partnership11,3050 (0.00%)0.04%$0 MNov 13, 2026
57Citigroup Inc10,881+6,810 (+167.28%)0.04%$0 MNov 4, 2026
58Atria Investments, Inc10,729-1,212 (-10.15%)0.04%$0 MOct 15, 2026
59Allegiance Financial Group Advisory Services LLC10,000New0.04%$0 MNov 2, 2026
60Persistent Asset Partners Ltd9,185-897 (-8.90%)0.03%$0 MNov 13, 2026
61Barclays PLC8,691+6,367 (+273.97%)0.03%$0 MNov 6, 2026
62Osaic Holdings, Inc.8,517-485 (-5.39%)0.03%$0 MNov 12, 2026
63Royal Bank Of Canada8,274-680 (-7.59%)0.03%$0 MNov 16, 2026
64Jpmorgan Chase & Co5,502+5,208 (+1771.43%)0.02%$0 MNov 12, 2026
65Vanguard Global Advisers, LLC4,6420 (0.00%)0.02%$0 MNov 13, 2026
66Tower Research Capital LLC (TRC)2,960-2,929 (-49.74%)0.01%$0 MNov 16, 2026
67Nuveen, LLC2,870New0.01%$0 MNov 10, 2026
68UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC1,345New0.00%$0 MNov 16, 2026
69PNC Financial Services Group, Inc.887-381 (-30.05%)0.00%$0 MNov 6, 2026
70Simplex Trading, LLC621New0.00%$0 MNov 4, 2026
71Jones Financial Companies Lllp570New0.00%$0 MNov 13, 2026
72Russell Investments Group, Ltd.465+216 (+86.75%)0.00%$0 MNov 6, 2026
73FMR LLC376-100 (-21.01%)0.00%$0 MNov 10, 2026
74Caitong International Asset Management Co., Ltd20+9 (+81.82%)0.00%$0 MOct 29, 2026

Mutual funds holding Journey Medical Corporation#

25 funds hold shares worth $22 M (about 10.5% of the company). Since their previous reports 12 added shares and 41 sold, selling $3 M net.
Mutual funds holding Journey Medical Corporation
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Wasatch Micro Cap FundWasatch Advisors LP1.30 M$9 M4.3%1.4%+58%Jun 30, 2026
🇺🇸 Wasatch Micro Cap Value FundWasatch Advisors LP788,173$6 M2.6%1.4%+9.4%Jun 30, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.470,426$3 M1.6%<0.01%−44%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.186,966$1 M0.62%<0.01%−19%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.105,535$1 M0.35%<0.01%+48%May 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC104,017$1 M0.35%<0.01%+45%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors50,931$0 M0.17%0.02%−1.2%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC41,381$0 M0.14%<0.01%+76%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC28,610$0 M0.10%<0.01%+53%May 31, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.19,126$0 M0.06%<0.01%+45%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC14,064$0 M0.05%<0.01%+62%May 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.10,418$0 M0.03%<0.01%−1.2%Jun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company8,545$0 M0.03%<0.01%+73%May 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.7,375$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC3,597$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC3,380$0 M0.01%0.01%−4.2%Jun 30, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP3,125$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.1,559$0 M<0.01%<0.01%−30%Jul 31, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.1,406$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC973$0 M<0.01%<0.01%+56%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC760$0 M<0.01%<0.01%−15%May 31, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC766$0 M<0.01%<0.01%−14%May 31, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC298$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.117$0 M<0.01%<0.01%+67%Jun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC79$0 M<0.01%<0.01%−27%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 25 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Journey Medical Corporation#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
11
since
$237 K-$811 K$0Nov 2023: bought $0 (0 trades), sold $18 K (3 trades)Nov 23Feb 2024: bought $0 (0 trades), sold $9 K (1 trades)FebMar 2024: bought $237 K (4 trades), sold $0 (0 trades)MarJul 2024: bought $0 (0 trades), sold $22 K (1 trades)JulAug 2024: bought $0 (0 trades), sold $51 K (1 trades)AugFeb 2025: bought $0 (0 trades), sold $7 K (1 trades)FebMar 2025: bought $0 (0 trades), sold $811 K (6 trades)MarMay 2025: bought $0 (0 trades), sold $69 K (3 trades)May
Bought (open market)Sold (open market)Hover a month for the totals
Journey Medical Corporation: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Miranda Jayne ToledanoDirectorGrant or award+50,000——168,618Form 4
filed Justin Adam SmithDirectorGrant or award+50,000——231,618Form 4
filed Neil HerskowitzDirectorGrant or award+50,000——168,618Form 4
filed Miranda Jayne ToledanoDirectorGrant or award+10,000——118,618Form 4
filed Justin Adam SmithDirectorGrant or award+10,000——181,618Form 4
filed Neil HerskowitzDirectorGrant or award+10,000——118,618Form 4
filed Michael Cooper PearceDirectorGrant or award+10,000——67,173Form 4
filed Lindsay A. RosenwaldDirectorGrant or award+10,000——221,146Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Journey Medical Corporation#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
3.1 M
15.07 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2025-05-15 13:35 UTC, code LUDP, resumed 13:40 UTC

Fails to deliver

  • : 579 shares at $6.61
  • : 110 shares at $6.72
  • : 16,031 shares at $6.32
  • : 200 shares at $7.29
  • : 476 shares at $7.38

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Journey Medical Corporation scorecard#

Passes 7 of the 22 checks that could be worked out: strongest in profitability (2 of 5), weakest in valuation (1 of 5). Fiscal year 2025; market cap of Oct 5, 2026.

  • Valuation1 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median5.9×Price to book 5.9× against Biotechnology's median of 2.9×.
    • ✓Price to sales below its peers' median2.7×Price to sales 2.7× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-12.9%Free cash flow is -12.9% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth2 of 6
    • ✓Revenue grew in the newest year10.2%Revenue up 10.2% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-5.7%-5.7% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-5.7%-5.7% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year-0.47 vs -0.72Diluted EPS -0.47 in fiscal 2025 against -0.72 the year before (report's currency).
    • ✗Net income higher than five years earlier-$11 M-$11 M in fiscal 2025 against $5 M in 2020.
    • ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
  • Profitability2 of 5
    • ✗Profitable in the newest year-$11 MNet income -$11 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✓Operating margin above its peers' median-13.2%-13.2% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-44.0%-44.0% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-13.2%-13.2% in fiscal 2025 against -37.4% in 2022.
  • Financial health2 of 5
    • ✓Short-term assets cover short-term liabilities1.8×Current ratio 1.79 at the end of fiscal 2025.
    • ✓Debt below equity0.8×Debt to equity 0.79 at the end of fiscal 2025.
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-2.2×Operating income -2.2 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone1.07Z-score 1.07 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year19.9%Diluted shares up 19.9% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Journey Medical Corporation's statements, beside the median of Biotechnology.

Journey Medical Corporation: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-13.2%-60.5%
Net margin-18.5%-68.9%
Return on equity-44.0%-61.0%
Revenue growth, 3 years a year-5.7%12.9%
Revenue growth10.2%15.8%
Debt to equity0.79×0.26×

4of 9on the Piotroski tests of financial strength

  • Net loss of $11 million, the 5th loss-making year in a row.
  • The share count rose 19.9% in the year.
  • Operating income covers the interest bill only -2.2 times.
  • Receivables grew 191% while revenue grew 10%: customers are paying later, or sales were booked ahead of cash.

Journey Medical Corporation: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Journey Medical Corporation: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Revenue625679746345
Cost of revenue212123r313215
Research and development0.59.97.5112.7—
Selling, general and administrative444044594022
Total costs and expenses7070811019837
Operating income−8.2−14−2.1−28−357.9
Interest expense and finance costs3.72.71.72.07.00.7
Other non-operating income (expense)−3.2−0.9−1.6−2.0−7.5−0.7
Income before tax−11−15−3.6−30−427.2
Income tax0.10.10.20.11.61.9
Net income including minority interests−11−15−3.9−30−445.3
Net income attributable to shareholders−11−15−3.9−30−445.3
Earnings per share, basic-0.47-0.72-0.21-1.69-4.320.58
Earnings per share, diluted-0.47-0.72-0.21-1.69-4.320.49
Shares, weighted average (basic)24201818109.1
Shares, weighted average (diluted)242018181011
Balance sheet
Cash and cash equivalents24202732498.2
Receivables301015282324
Inventory9.61410149.91.4
Other current assets3.43.23.63.32.41.7
Current assets674856788435
Right-of-use (leased) assets0.10.20.10.20.10.2
Other intangible assets283220271315
Total assets9580771059752
Accounts payable8.9161837231.8
Current liabilities3735426752r28
Long-term debt25251520——
Lease liabilities (non-current)0.00.10.00.1—0.1
Total liabilities636056885542
Retained earnings−98−87−72−69−395.1
Shareholders' equity322020174210
Total liabilities and equity9580771059752
Shares outstanding————113.2
Cash-flow statement
Depreciation and amortization————00.0
Share-based compensation6.36.12.64.42.50.2
Cash from operating activities−12−9.15.2−14−2.25.1
Capital expenditure—−15−5.0−20——
Intangible assets bought————−10−1.2
Cash from investing activities—−15−5.0−20−10−1.2
Shares issued167.94.5—33—
Cash from financing activities1617−4.81653−0.5
Change in cash3.8−7.1−4.6−17413.4
Report10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Journey Medical Corporation sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Qbrexza$25 M40%
  • Emrosi$15 M24%
  • Accutane$13 M21%
  • Foam franchise products (Amzeeq & Zilxi)$6 M9.5%
  • Other / legacy$3 M4.4%

Business segments

  • Dermatological segment$62 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Events at Journey Medical Corporation#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 4 · Material agreement 3 · Agreement ended 1 · New debt 2 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 13

Journey Medical Corporation: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Material agreementNew debt8-K
Material agreementAgreement ended8-K
Results announced8-K
Bylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Directors and officersMaterial agreementNew debt8-K
Directors and officersShareholder vote8-K
Results announced8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Journey Medical Corporation
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2021$19 MNo. 1$10 to $50 million146equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Journey Medical Corporation#

1 labor condition applications certified in fiscal 2023 for 1 positions, at a median wage of $180 K a year.

Certified, FY2023
1
#2,002 among companies on value.today
Worker positions
1
Median wage offered
$180 K
a year, full-time
Applications filed
1
Journey Medical Corporation: most frequent H-1B job titles in fiscal 2023
Job titlePositionsMedian wage offered
Senior Director – Regulatory Affairs & QualityRegulatory Affairs Managers1$180 K

Where: Scottsdale, AZ 1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Journey Medical Corporation

How Journey Medical Corporation compares in Biotechnology

  • Market cap$187 M · higher than 43% of 726
  • Revenue$62 M · higher than 62% of 647
  • Net margin-7.3% · higher than 66% of 408
  • Revenue growth10.2% · higher than 53% of 438
  • Price / sales2.7× · lower than 80% of 339
  • Price / book5.9× · lower than 26% of 534
  • FCF yield-12.9% · higher than 52% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Journey Medical Corporation🇺🇸$187 M—-7.3%+10.2%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 5, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of March 18, 2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Journey Medical Corporation? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Journey Medical Corporation's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Journey Medical Corporation? Suggest a correction